ZA200409776B - Immunoadhesin comprising a glycoprotein VI domain - Google Patents

Immunoadhesin comprising a glycoprotein VI domain

Info

Publication number
ZA200409776B
ZA200409776B ZA200409776A ZA200409776A ZA200409776B ZA 200409776 B ZA200409776 B ZA 200409776B ZA 200409776 A ZA200409776 A ZA 200409776A ZA 200409776 A ZA200409776 A ZA 200409776A ZA 200409776 B ZA200409776 B ZA 200409776B
Authority
ZA
South Africa
Prior art keywords
domain
glycoprotein
fusion protein
immunoadhesin
provides
Prior art date
Application number
ZA200409776A
Other languages
English (en)
Inventor
Massberg Steffen
Gawaz Meinrad
Bueltmann Andreas
Goetz Muench
Ungerer Martin
Peluso Mario
Original Assignee
Trigen Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trigen Gmbh filed Critical Trigen Gmbh
Publication of ZA200409776B publication Critical patent/ZA200409776B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
ZA200409776A 2002-06-07 2004-12-02 Immunoadhesin comprising a glycoprotein VI domain ZA200409776B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02012742A EP1369128A1 (fr) 2002-06-07 2002-06-07 Inhibiteurs de glycoprotéine VI et leur utilisation thérapeutique

Publications (1)

Publication Number Publication Date
ZA200409776B true ZA200409776B (en) 2007-02-28

Family

ID=29433140

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200409776A ZA200409776B (en) 2002-06-07 2004-12-02 Immunoadhesin comprising a glycoprotein VI domain

Country Status (13)

Country Link
US (1) US7514543B2 (fr)
EP (4) EP1369128A1 (fr)
JP (1) JP4722480B2 (fr)
CN (1) CN1668721B (fr)
AT (1) ATE346095T1 (fr)
AU (2) AU2003250825A1 (fr)
CA (1) CA2488630C (fr)
DE (1) DE60309865T2 (fr)
DK (1) DK1860118T3 (fr)
ES (2) ES2527717T3 (fr)
SI (1) SI1511770T1 (fr)
WO (2) WO2003104282A2 (fr)
ZA (1) ZA200409776B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
GB0511590D0 (en) * 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
EP1369128A1 (fr) 2002-06-07 2003-12-10 Procorde GmbH Inhibiteurs de glycoprotéine VI et leur utilisation thérapeutique
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
WO2005111083A2 (fr) * 2004-04-29 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Anticorps diriges contre la glycoproteine vi et procedes associes
ES2534288T3 (es) 2004-08-03 2015-04-21 Innate Pharma Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3
EP1824979A2 (fr) * 2004-12-10 2007-08-29 Trigen GmbH Procedes, produits et utilisations relatifs a des plaquettes et/ou la vasculature
FR2884831B1 (fr) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
JP5224707B2 (ja) * 2005-04-28 2013-07-03 持田製薬株式会社 抗血小板膜糖蛋白質viモノクローナル抗体
CA2606450A1 (fr) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anticorps monoclonal anti-glycoproteine vi de membrane plaquettaire
US20090041783A1 (en) * 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
CA2639624A1 (fr) * 2005-12-22 2007-06-28 Shionogi & Co., Ltd. Procede de prediction de pronostic de syndrome coronaire aigu
US20100297116A1 (en) * 2007-10-31 2010-11-25 Yongge Liu Uses of a glycoprotein vi (gpvi) inhibitor
US9012221B2 (en) * 2008-12-04 2015-04-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for producing platelets from megakaryocytes
AU2010246872B2 (en) * 2009-05-15 2015-01-22 The Hospital For Sick Children Compositions and methods for treating hematologic cancers targeting the SIRPalpha - CD47 interaction
EP2397495A1 (fr) * 2010-06-21 2011-12-21 Sanofi Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EP2336188A1 (fr) * 2009-12-18 2011-06-22 Sanofi-Aventis Nouveaux anticorps antagonistes et leurs fragments Fab contre le GPVI et leurs utilisations
EA201290525A1 (ru) * 2009-12-18 2013-01-30 Санофи Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения
EP2377888A1 (fr) 2010-04-07 2011-10-19 Corimmun GmbH Protéine de fusion
HUE058790T2 (hu) 2012-12-17 2022-09-28 Pf Argentum Ip Holdings Llc CD47+ beteg sejtek kezelése SIRP-alfa-Fc fúziókkal
CA2895693C (fr) * 2012-12-20 2017-02-28 Fujimori Kogyo Co., Ltd. Methode d'evaluation complete d'agregation plaquettaire
EP3424957A1 (fr) 2017-07-03 2019-01-09 advanceCOR GmbH Protéine de fusion
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技(上海)有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
WO2021158878A1 (fr) * 2020-02-06 2021-08-12 Boehringer Ingelheim Animal Health USA Inc. Polypeptides utiles pour la détection d'anticorps anti-rhabdovirus

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) * 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
ZA887365B (en) 1987-10-02 1990-05-30 Genentech Inc Adheson variants
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
GB9806806D0 (en) 1998-03-30 1998-05-27 Univ Cambridge Tech Peptides and uses thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9810999D0 (en) * 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
RU2287580C2 (ru) 1999-05-07 2006-11-20 Авентис Фарма Дойчланд Гмбх Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин vi и его применение в фармацевтике
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001016321A1 (fr) 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Adn et sequences proteiniques de glycoproteine vi (gpvi) de membranes plaquettaires et utilisations de ceux-ci
EP1224942A1 (fr) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Utilisation de JAQ1 (anticorps monoclonal anti-GPVI) en tant que médicament actif pour la protection contre les maladies thrombotiques
SG157961A1 (en) 2001-05-25 2010-01-29 Univ Duke Modulators of pharmacological agents
AU2002333241B2 (en) 2001-07-18 2008-09-18 Merck Patent Gmbh Glycoprotein VI fusion proteins
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
GB0130832D0 (en) 2001-12-22 2002-02-06 Univ Reading Modulation of the activity of the platelet endothelial cell adhesion molecule-1 (pecam-1)
GB0211750D0 (en) 2002-05-22 2002-07-03 Ouwehand Willem Abnormal blood conditions
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (fr) 2002-06-07 2003-12-10 Procorde GmbH Inhibiteurs de glycoprotéine VI et leur utilisation thérapeutique
EP1538165A1 (fr) 2003-12-03 2005-06-08 Procorde GmbH Inhibiteurs de la glycoprotéine VI construits à partir de l'anticorps monoclonal hgp 5c4

Also Published As

Publication number Publication date
JP4722480B2 (ja) 2011-07-13
EP1511770A2 (fr) 2005-03-09
ATE346095T1 (de) 2006-12-15
WO2003104282A2 (fr) 2003-12-18
CA2488630C (fr) 2011-07-05
EP1511480A2 (fr) 2005-03-09
CN1668721B (zh) 2012-11-14
EP1860118A3 (fr) 2008-07-30
CA2488630A1 (fr) 2003-12-18
WO2003103662A3 (fr) 2004-11-04
AU2003250825A1 (en) 2003-12-22
EP1860118A2 (fr) 2007-11-28
WO2003104282A3 (fr) 2004-10-14
ES2527717T3 (es) 2015-01-28
WO2003103662A2 (fr) 2003-12-18
DK1860118T3 (en) 2015-02-09
US20050079541A1 (en) 2005-04-14
EP1511770B1 (fr) 2006-11-22
DE60309865T2 (de) 2007-10-18
AU2003250825A8 (en) 2003-12-22
AU2003236704B2 (en) 2010-07-08
DE60309865D1 (de) 2007-01-04
EP1369128A1 (fr) 2003-12-10
US7514543B2 (en) 2009-04-07
SI1511770T1 (sl) 2007-04-30
ES2276078T3 (es) 2007-06-16
AU2003236704A1 (en) 2003-12-22
WO2003104282A8 (fr) 2004-04-29
JP2006512894A (ja) 2006-04-20
EP1860118B1 (fr) 2014-12-31
CN1668721A (zh) 2005-09-14

Similar Documents

Publication Publication Date Title
ZA200409776B (en) Immunoadhesin comprising a glycoprotein VI domain
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
PT2360176E (pt) Expressão híbrida e em série de proteínas derivadas de neisseria
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
DK2020604T3 (da) Ligand for den G-proteinkoblede receptor FPRL2
WO2002103024A3 (fr) Proteines stabilisees avec des liaisons disulfure genetiquement modifiees
EP1479768A4 (fr) Nouveau procede de criblage
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
EA200501756A1 (ru) Химерные гибриды мономер-димер иммуноглобулина
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
DE59914490D1 (de) Ein faktor viii-polypeptid mit faktor viii:c-aktivität
ATE290088T1 (de) Verfahren zur spaltung eines chimeren proteins mittels eines 'processing'-enzyms
DE69635161D1 (de) Rekombinante hetero-multimerische proteine von dem alpha-beta c4 bp typ
WO2004090103A8 (fr) Identification de nouveaux nogo-recepteurs et procedes associes
ATE414164T1 (de) Verfahren zur kontrolle der spaltung mit ompt protease
EP1584925A4 (fr) Nouveau procede de criblage
ATE367438T1 (de) Verfahren zur steigerung der expression von menschlichen tnf-rezeptor
EP1467207A4 (fr) Methode de criblage
EP1617216A4 (fr) Nouvelle technique de criblage
ATE525396T1 (de) Slo2 und slo4, neue kaliumkanal-proteine aus menschlichem gehirn